Medical/Pharmaceuticals
Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
SHANGHAI and NEW YORK, June 10, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leadingShanghai-based high-tech biopharmaceutical company specializing in biologics R&D today announced the signing of a strategic cooperation agreement with Medicovestor, Inc., aNew York-based biotechnology company...
2025-06-10 18:00
1877
Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
* LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals inthe United States and Europe, who progress rapidly to end-stage heart failure. * NVC-001 demonstrated significant benefits, including survival and cardiac ...
2025-06-10 16:49
1582
Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025
* Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world's largest biotech industry event. * For the first time at an international conference, Caliway will share preclinical results on CBL-514's potential new indication: combined withGLP-1 ...
2025-06-10 16:15
1840
ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR),Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedT...
2025-06-10 13:45
2252
Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT
SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for pimicotinib, a highly selective, small-molecule CSF-1R inhibitor, as a Class 1 innovati...
2025-06-10 12:02
1909
New Survey Finds Younger Adults, More Women Seeking Treatment for Hair Loss
Manageable number of monthly hair restoration surgeries illustrates ISHRS members' hands-on, expert approach CHICAGO, June 10, 2025 /PRNewswire/ -- According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), first-time hair restoration ...
2025-06-10 09:00
2003
Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing
OSAKA, Japan, June 10, 2025 /PRNewswire/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary — a milestone that reflects two decades of dedication to improving health outcomes through high-quality, patient-centered research. Since its founding in 2005 in...
2025-06-10 09:00
1753
Akesis Biologics Launches MastGut: A Breakthrough Supplement That Uses DUSP10 Enzyme to Support Gut and Colorectal Health
SINGAPORE, June 10, 2025 /PRNewswire/ -- Akesis Biologics, a biotechnology spin-off from the National University of Singapore (NUS), has officially launched its flagship gut health product,MastGut — a pioneering supplement that delivers therapeutic protection directly to the gut. Built on years o...
2025-06-10 08:45
1640
Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care
PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated
steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed
drivers of liver failure—affecting more than 250 million people worldwide—
Echosens
2025-06-10 06:00
1952
VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.
HONG KONG and WENZHOU, China, June 9, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today that it received written preliminary comments for the Type C meeting to be held in e...
2025-06-10 00:00
1967
Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)
* EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R * Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels * No Safety Issues Observed Following a Single Intravitreal (IVT) Injection * Multiple Ascending Dose Study Planned for Q3 2025 in DME MOUNTAIN VIEW, Calif., J...
2025-06-10 00:00
2040
World's First HLA-G Targeted Exosome Therapy for Cancer Enters U.S. Clinical Trials
FDA Greenlights SOB100 for Phase I; Breakthrough Study Published in Nature Communications TAICHUNG, June 9, 2025 /PRNewswire/ -- A research team led by Dr. Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in collaboration with Shine-On Biomedical Co., has developed the...
2025-06-09 20:03
1703
Planet Green Advances AI-Powered Early Mental Health Intervention for Youth in Post-Pandemic Canada
NEW YORK, June 9, 2025 /PRNewswire/ -- Planet Green Holdings Corp. ("Planet Green", the "Company") (NYSE American: PLAG) announced that its subsidiary Fast Approach Inc., ("Fast Approach"), a leader in applied AI technology, today announced a groundbreaking initiative in mental healthcare: the de...
2025-06-09 20:00
3454
Neowise Biotechnology and BeOne Medicines Enter Licensing Agreement to Advance Development of Next-Generation Cell Therapies
SUZHOU, China, June 9, 2025 /PRNewswire/ -- Neowise Biotechnology ("Neowise"), a pioneering company focused on the development of TCR-T cell therapies for solid tumors, announced today that it has entered into a non-exclusive licensing agreement with BeOne Medicines Ltd. ("BeOne"). Under the term...
2025-06-09 20:00
1750
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, andTaiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ ...
2025-06-09 19:00
2128
Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of its FIH Study
TEL AVIV, Israel, June 9, 2025 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, is happy to announce the first U.S. implantations of its atrial-pressure microsensor. Two surgical implantations were performed on Friday, May 16, 2025, at New York-Presbyterian/Columbia University Irv...
2025-06-09 18:00
1993
BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration
China's influential innovative drug asset cooperation platform NEWARK, Del., June 9, 2025 /PRNewswire/ -- BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSee...
2025-06-09 14:51
1965
Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association
* EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSG...
2025-06-09 14:16
2291
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small moleculeGLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be present...
2025-06-09 08:15
2007
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in
non-invasive medical aesthetic technology, has successfully hosted its
inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand
on June 5th.
2025-06-07 18:21
2464
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 310 media titles]
2026-01-15 13:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 301 media titles]
2026-01-21 12:39JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 296 media titles]
2026-01-15 10:00Infobip strengthens leadership to drive growth and innovation
[Picked up by 281 media titles]
2026-01-16 11:00
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 279 media titles]
2026-01-20 15:40
